BRPI1014571B8 - Composições de combinação de lactona macrocíclica, vacinas e métodos para produção das mesmas - Google Patents

Composições de combinação de lactona macrocíclica, vacinas e métodos para produção das mesmas

Info

Publication number
BRPI1014571B8
BRPI1014571B8 BRPI1014571A BRPI1014571A BRPI1014571B8 BR PI1014571 B8 BRPI1014571 B8 BR PI1014571B8 BR PI1014571 A BRPI1014571 A BR PI1014571A BR PI1014571 A BRPI1014571 A BR PI1014571A BR PI1014571 B8 BRPI1014571 B8 BR PI1014571B8
Authority
BR
Brazil
Prior art keywords
vaccines
viral
macrocyclic lactone
diseases
production
Prior art date
Application number
BRPI1014571A
Other languages
English (en)
Inventor
William Lachlan Holmes Robert
Hameed Abdul Razzak Majid
Original Assignee
Merial Ltd
Merial Inc
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Merial Inc, Boehringer Ingelheim Animal Health Usa Inc filed Critical Merial Ltd
Publication of BRPI1014571A2 publication Critical patent/BRPI1014571A2/pt
Publication of BRPI1014571B1 publication Critical patent/BRPI1014571B1/pt
Publication of BRPI1014571B8 publication Critical patent/BRPI1014571B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES DE COMBINAÇÃO DE LACTONA MACROCÍCLICA, VACINAS E PROCESSOS PARA PRODUZIR AS MESMAS Uma composição injetável, capaz de prevenir ou controlar infecções parasitárias, virais ou bacterianas ou doenças, por exemplo, disenteria, em vacas gestantes e infecções virais ou doenças em bezerros recém-nascidos por por administração via parental a cada vaca em um rebanho de vacas prenhes, uma dose de uma composição de combinação compreendendo: (a) pelo menos um componente viral inativadoderivado do rotavírus e/ou coronavírus; (b) um composto ativo de lactona macrocíclica, e (c) um veículo parenteral e conservante farmaceuticamente aceitável. As composições injetáveis que incluem eprinomectina resultam em resíduos de leite extremamente baixos.
BRPI1014571A 2009-04-14 2010-04-14 Composições de combinação de lactona macrocíclica, vacinas e métodos para produção das mesmas BRPI1014571B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ576201 2009-04-14
NZ57620109 2009-04-14
NZ57639109 2009-04-20
NZ576391 2009-04-20
NZ2010120195 2010-10-21

Publications (3)

Publication Number Publication Date
BRPI1014571A2 BRPI1014571A2 (pt) 2016-04-26
BRPI1014571B1 BRPI1014571B1 (pt) 2021-08-10
BRPI1014571B8 true BRPI1014571B8 (pt) 2022-06-28

Family

ID=42981142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014571A BRPI1014571B8 (pt) 2009-04-14 2010-04-14 Composições de combinação de lactona macrocíclica, vacinas e métodos para produção das mesmas

Country Status (14)

Country Link
US (1) US8313752B2 (pt)
EP (1) EP2419131B1 (pt)
AU (1) AU2010237070B2 (pt)
BR (1) BRPI1014571B8 (pt)
CA (1) CA2758276C (pt)
CO (1) CO6450627A2 (pt)
CY (1) CY1116630T1 (pt)
DK (1) DK2419131T3 (pt)
ES (1) ES2546480T3 (pt)
MX (1) MX2011010710A (pt)
PL (1) PL2419131T3 (pt)
PT (1) PT2419131E (pt)
WO (1) WO2010120195A1 (pt)
ZA (1) ZA201107324B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440203B2 (en) 2009-11-06 2013-05-14 Intervet Inc. Methods of immunizing pregnant heifers at three months of gestation
WO2011143479A1 (en) * 2010-05-12 2011-11-17 Merial Limited Injectable parasiticidal formulations of levamisole and macrocyclic lactones
WO2014098623A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Injectable eprinomectin formulation and anthelmintic use thereof
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
AU2020251960A1 (en) * 2019-04-04 2021-11-11 Tarsus Pharmaceuticals, Inc. Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
AU2021233700A1 (en) * 2020-03-13 2022-11-10 Melbourne Health Viral inhibition
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
CN114642632A (zh) * 2022-02-25 2022-06-21 河北科技大学 一种莫西克汀注射液及其制备方法
CA3246927A1 (en) * 2022-03-27 2023-10-05 Kirill Didenko Highly permeable, bioavailable processes and compounds for the treatment of viral diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191413A (en) 1978-09-11 1981-10-19 Ici Australia Ltd Anthelmintic and anticlostridial composition containing a tetramisole salt
US5284877A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
ATE214603T1 (de) * 1995-06-30 2002-04-15 American Cyanamid Co Stabile makrolide und makrolide imptstoff- zusammensetzungen
EP0928136B1 (en) * 1996-06-05 2003-10-22 Ashmont Holdings Limited Injectable compositions
US6974577B2 (en) * 2001-02-04 2005-12-13 Novartris Ag Inactivated bovine scours vaccines, processes and method of preventing bovine scours
UY27412A1 (es) 2002-08-12 2003-06-30 Carlson Internat Inc Un nuevo producto para el combate de garrapatas y el proceso para la prepaacinn.
US6653288B1 (en) * 2002-09-30 2003-11-25 Virbac S.A. Injectable anthelmintic compositions and methods for using same
LT1610613T (lt) 2003-04-04 2017-03-27 Merial, Inc. Vietinio taikymo antihelmintinės veterinarinės kompozicijos

Also Published As

Publication number Publication date
CA2758276A1 (en) 2010-10-21
ZA201107324B (en) 2012-07-25
CO6450627A2 (es) 2012-05-31
CY1116630T1 (el) 2017-03-15
EP2419131A1 (en) 2012-02-22
PL2419131T3 (pl) 2015-11-30
EP2419131B1 (en) 2015-06-03
DK2419131T3 (en) 2015-06-29
CA2758276C (en) 2018-01-23
US20100266628A1 (en) 2010-10-21
BRPI1014571B1 (pt) 2021-08-10
WO2010120195A1 (en) 2010-10-21
PT2419131E (pt) 2015-09-28
AU2010237070B2 (en) 2015-03-26
US8313752B2 (en) 2012-11-20
MX2011010710A (es) 2012-01-25
ES2546480T3 (es) 2015-09-24
EP2419131A4 (en) 2013-01-09
BRPI1014571A2 (pt) 2016-04-26
AU2010237070A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
CO6450627A2 (es) Composiciones de combinación de lactoma macrocíclica, vacunas y métodos para producirlas
MX381845B (es) Combinación, composición y método de administración de la combinación o composición a animales.
WO2008073891A3 (en) Salmonella vaccine in poultry
GEP201706772B (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
UA103298C2 (ru) Способ лечения молодых свиней с помощью антигена pcv2
EA201190012A1 (ru) Твердые лекарственные формы бендамустина
MX2019010598A (es) Composicion farmaceutica que comprende selexipag.
UY32599A (es) Formulación oral sólida de abt-263
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
UA110328C2 (en) Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
BRPI0922806B8 (pt) composição farmacêutica oral compreendendo bendamustina
NZ596099A (en) Milk oligosaccharide compositions and use thereof in treating infection in animals
MX371329B (es) Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv).
CR20150508A (es) Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles
MX363044B (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
DOP2025000185A (es) Composición inyectable, formulación farmacéutica que incluye la misma y método para preparar la composición
MX2019002386A (es) Uso de oligosacaridos de leche humana en el engorde de terneros.
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
NZ594610A (en) Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
NZ760663A (en) Dual active parasiticidal granule compositions, methods and uses thereof
RU2013131611A (ru) Средство для лечения энтеритов у животных
Smaldone et al. Alphacypermethrin residues in milk following a pour-on treatment in buffaloes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25G Requested change of headquarter approved

Owner name: MERIAL LIMITED (US)

B25A Requested transfer of rights approved

Owner name: MERIAL, INC. (US)

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)